Guggenheim Capital’s Akero Therapeutics AKRO Stock Holding History

Guggenheim Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,216	Closed	-$1.05M	–	1745
2025 Q3	$1.05M	Buy	22,216 +1,069	+5%	+$51.8K	0.01%	903
2025 Q2	$1.13M	Buy	21,147 +15,204	+256%	+$691K	0.01%	843
2025 Q1	$241K	Buy	+5,943	New	+$252K	﹤0.01%	1482
2024 Q4	–	Sell	-25,198	Closed	-$723K	–	1690
2024 Q3	$723K	Sell	25,198 -6,705	-21%	-$175K	0.01%	1248
2024 Q2	$748K	Buy	31,903 +6,866	+27%	+$147K	0.01%	1252
2024 Q1	$632K	Sell	25,037 -6,185	-20%	-$149K	﹤0.01%	1371
2023 Q4	$729K	Buy	+31,222	New	+$616K	0.01%	1295

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Guggenheim Capital's AKRO Position: Q4 2025 in Review

Guggenheim Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 22,216 shares — an estimated $1.05M sold.

Guggenheim Capital first reported a position in AKRO in Q4 2023 and held it in 7 quarters. The position peaked at $1.13M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Guggenheim Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Guggenheim Capital sold 22,216 Akero Therapeutics shares in Q4 2025, an estimated $1.05M.
Guggenheim Capital first reported a position in Akero Therapeutics in Q4 2023 and held it in 7 quarters.
Guggenheim Capital's Akero Therapeutics position peaked at $1.13M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Guggenheim Capital's 13F filing for Q4 2025, filed 17 Feb 2026.